Table 3.
Univariate and multivariate Cox regression analyses for Progression-Free Survival in propensity score-matched cohort.
| Variables | Comparison | Univariate analysis | P-value | Multivariate analysis | P-value | ||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | ||||
| Age, years | Increase per year | 1.01 | 0.99–1.05 | 0.887 | |||
| Sex | Female vs Male | 1.11 | 0.77–1.59 | 0.578 | |||
| HBV | Yes vs No | 1.2 | 0.87–1.67 | 0.268 | |||
| HCV | Yes vs No | 0.98 | 0.69–1.4 | 0.92 | |||
| ALBI Grade | II vs I | 1.64 | 1.19–2.28 | 0.003 | 1.53 | 1.08–2.17 | 0.016 |
| BCLC stage | C vs B | 1.15 | 0.74–1.79 | 0.525 | |||
| EHM | Yes vs No | 0.91 | 0.66–1.25 | 0.547 | |||
| MVI | Yes vs No | 1.23 | 0.89–1.7 | 0.22 | |||
| AFP ≥200 ng/ml | Yes vs No | 1.72 | 1.24–2.39 | 0.001 | 1.77 | 1.23–2.53 | 0.002 |
| Dose reduction | Yes vs No | 0.94 | 0.65–1.36 | 0.745 | |||
| Combined treatment | Yes vs No | 0.77 | 0.54–1.1 | 0.156 | |||
| Treatment option | Lenvatinib vs Sorafenib | 0.66 | 0.46–0.94 | 0.021 | 0.49 | 0.3–0.79 | 0.004 |
AFP, alpha fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; EHM; extrahepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MVI, macrovascular invasion.